Literature DB >> 20190601

Prolongation of QT interval induced by electroconvulsive therapy is attenuated by landiolol.

Masayo Matsura1, Yoshihiro Fujiwara, Hiroshi Ito, Nobuhisa Kandatsu, Naoko Kato, Jun Harada, Toru Komatsu.   

Abstract

OBJECTIVE: The objective of this study was to determine if landiolol, ultra short-acting beta adrenoceptor antagonist, attenuates the prolongation of QT interval caused by electroconvulsive therapy (ECT).
METHODS: Fifteen patients, scheduled to undergo ECT for the treatment of major depression disorder, were studied. In each patient, 2 sessions of ECT were picked up and randomly assigned to be administered with (treatment L) or without continuous infusion of landiolol (treatment C). Electroconvulsive therapy was administered under general anesthesia with propofol and suxamethonium. Raw electrocardiogram waves were obtained from anesthesia monitor and stored on a personal computer. Automated electrocardiogram analyzing software was used for the determination of QT interval.
RESULTS: The increase in corrected QT caused by suxamethonium was significantly smaller in treatment L (36.8 +/- 14.5 ms for treatment C vs 17.9 +/- 6.5 ms for treatment L; P < 0.001). The increase in corrected QT caused by ECT was also smaller in treatment L (72.3 +/- 23.1 ms for treatment C vs 54.6 +/- 17.9 ms for treatment L; P = 0.02).
CONCLUSIONS: The prolongation of QT interval caused by SUX and ECT was partially attenuated by landiolol.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20190601     DOI: 10.1097/YCT.0b013e3181a95d8c

Source DB:  PubMed          Journal:  J ECT        ISSN: 1095-0680            Impact factor:   3.635


  2 in total

1.  A case of nonsustained ventricular tachycardia immediately following modified electroconvulsive therapy in a depressive patient.

Authors:  Yukari Koga; Yasunori Mishima; Masahiro Momozaki; Teruyuki Hiraki; Kazuo Ushijima
Journal:  J Anesth       Date:  2011-05-15       Impact factor: 2.078

Review 2.  Landiolol: a review of its use in intraoperative and postoperative tachyarrhythmias.

Authors:  Greg L Plosker
Journal:  Drugs       Date:  2013-06       Impact factor: 9.546

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.